Annual ROA
-131.17%
-58.77%-81.17%
31 December 2023
Summary:
Inhibikase Therapeutics annual return on assets is currently -131.17%, with the most recent change of -58.77% (-81.17%) on 31 December 2023. During the last 3 years, it has fallen by -92.74% (-241.32%). IKT annual ROA is now -276.71% below its all-time high of -34.82%, reached on 31 December 2021.IKT ROA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROA
-201.82%
-61.18%-43.50%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly return on assets is currently -201.82%, with the most recent change of -61.18% (-43.50%) on 30 September 2024. Over the past year, it has dropped by -119.83% (-146.15%). IKT quarterly ROA is now -428.74% below its all-time high of -38.17%, reached on 31 March 2022.IKT Quarterly ROA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT ROA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -81.2% | -146.2% |
| 3 y3 years | -241.3% | -354.0% |
| 5 y5 years | -73.5% | - |
IKT ROA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -276.7% | at low | -428.7% | at low |
| 5 y | 5 years | -276.7% | +66.9% | -428.7% | +98.7% |
| alltime | all time | -276.7% | +66.9% | -428.7% | +98.7% |
Inhibikase Therapeutics ROA History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -201.82%(+43.5%) |
| June 2024 | - | -140.64%(+20.5%) |
| Mar 2024 | - | -116.72%(+27.1%) |
| Dec 2023 | -131.17%(+81.2%) | -91.82%(+12.0%) |
| Sept 2023 | - | -81.99%(+12.1%) |
| June 2023 | - | -73.17%(+18.3%) |
| Mar 2023 | - | -61.87%(+7.9%) |
| Dec 2022 | -72.40% | -57.36%(+9.3%) |
| Sept 2022 | - | -52.48%(+12.2%) |
| June 2022 | - | -46.77%(+22.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | -38.17%(-3.6%) |
| Dec 2021 | -34.82%(-9.4%) | -39.58%(-11.0%) |
| Sept 2021 | - | -44.45%(-3.4%) |
| June 2021 | - | -46.02%(-46.8%) |
| Mar 2021 | - | -86.55%(+1.4%) |
| Dec 2020 | -38.43%(-90.3%) | -85.32%(-80.4%) |
| Sept 2020 | - | -434.23%(-75.5%) |
| June 2020 | - | -1770.47%(-85.2%) |
| Mar 2020 | - | -11.93 K%(-20.1%) |
| Dec 2019 | -396.78%(+424.7%) | -14.94 K% |
| Dec 2018 | -75.62% | - |
FAQ
- What is Inhibikase Therapeutics annual return on assets?
- What is the all time high annual ROA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual ROA year-on-year change?
- What is Inhibikase Therapeutics quarterly return on assets?
- What is the all time high quarterly ROA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly ROA year-on-year change?
What is Inhibikase Therapeutics annual return on assets?
The current annual ROA of IKT is -131.17%
What is the all time high annual ROA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual return on assets is -34.82%
What is Inhibikase Therapeutics annual ROA year-on-year change?
Over the past year, IKT annual return on assets has changed by -58.77% (-81.17%)
What is Inhibikase Therapeutics quarterly return on assets?
The current quarterly ROA of IKT is -201.82%
What is the all time high quarterly ROA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly return on assets is -38.17%
What is Inhibikase Therapeutics quarterly ROA year-on-year change?
Over the past year, IKT quarterly return on assets has changed by -119.83% (-146.15%)